Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Pharma
AZ, Boehringer-Simcere, Daiichi and more—Fierce Pharma Asia
AZ pledged a $15 billion China investment. BI and Simcere inked a potential $1 billion IBD deal. Daiichi is navigating a complex ADC market. And more.
Angus Liu
Jan 30, 2026 7:45am
J&J survey underscores the power of patient community in IBD
Nov 7, 2025 5:00pm
AbbVie taps Tyler James Williams for new IBD campaign
Oct 7, 2025 2:12pm
J&J pads Tremfya IBD offerings with subQ ulcerative colitis nod
Sep 22, 2025 11:01am
J&J's Tremfya picks up key FDA nod in Crohn's disease
Mar 20, 2025 7:56pm
As IBD sales boom, AbbVie increases Skyrizi, Rinvoq projection
Jan 31, 2025 11:41am
